We are live on ! Find out more
ANIP icon

ANI Pharmaceuticals
ANIP

126 hedge funds and large institutions have $391M invested in ANI Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 46 increasing their positions, 33 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

39% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 33

32% more call options, than puts

Call options by funds: $905K | Put options by funds: $688K

18% more capital invested

Capital invested by funds: $330M → $391M (+$61M)

6% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 18

0% more funds holding

Funds holding: 126 → 126 (0)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.18% less ownership

Funds ownership: 58.92% → 58.74% (-0.18%)

Holders
126
Holders Change
–
Holders Change %
0%
% of All Funds
2.03%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
19
Increased
46
Reduced
33
Closed
18
Calls
$905K
Puts
$688K
Net Calls
+$217K
Net Calls Change
+$1.21M

Top Buyers

1
RCMNY
Rubric Capital Management (New York)
New York
+$3.35M
2
BlackRock
BlackRock
New York
+$2.2M
3
ACM
AIGH Capital Management
Maryland
+$1.64M
4
SSA
Schonfeld Strategic Advisors
New York
+$1.5M
5
RCAMU
Rothschild & Co Asset Management US
Connecticut
+$1.31M

Top Sellers

1
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$4.47M
2
TCM
Tang Capital Management
California
-$3.21M
3
SCM
Sio Capital Management
New York
-$1.29M
4
LSV Asset Management
LSV Asset Management
Illinois
-$1.14M
5
JCIA
Jackson Creek Investment Advisors
Colorado
-$1.03M
Name Holding Trade Value Shares
Change 		Change in
Stake
Invesco
26
Invesco
Georgia
$2.92M +$248K +6,603 +10%
Goldman Sachs
27
Goldman Sachs
New York
$2.91M -$760K -20,240 -22%
Comerica Bank
28
Comerica Bank
Texas
$1.98M -$24.2K -643 -1%
N
29
Nuveen
North Carolina
$1.81M -$230K -6,115 -12%
SSA
30
Schonfeld Strategic Advisors
New York
$1.6M +$1.5M +39,846 New
JP Morgan Chase
31
JP Morgan Chase
New York
$1.57M +$133K +3,545 +10%
RCAMU
32
Rothschild & Co Asset Management US
Connecticut
$1.4M +$1.31M +34,924 New
Charles Schwab
33
Charles Schwab
California
$1.39M +$51.5K +1,371 +4%
RhumbLine Advisers
34
RhumbLine Advisers
Massachusetts
$1.27M +$34.8K +926 +3%
Swiss National Bank
35
Swiss National Bank
Switzerland
$1.27M +$30K +800 +3%
Legal & General Group
36
Legal & General Group
United Kingdom
$1.2M +$38.3K +1,021 +4%
Millennium Management
37
Millennium Management
New York
$1.07M -$948K -25,234 -49%
Jane Street
38
Jane Street
New York
$1.06M +$993K +26,447 New
Bank of America
39
Bank of America
North Carolina
$1.02M +$347K +9,245 +58%
PAM
40
Panagora Asset Management
Massachusetts
$1.01M +$588K +15,649 +167%
RP
41
Regal Partners
Australia
$1.01M +$939K +25,000 New
DC
42
Defender Capital
North Carolina
$966K – – –
MUAMU
43
Mitsubishi UFJ Asset Management (UK)
United Kingdom
$925K – – –
Public Sector Pension Investment Board (PSP Investments)
44
Public Sector Pension Investment Board (PSP Investments)
Quebec, Canada
$890K – – –
New York State Teachers Retirement System (NYSTRS)
45
New York State Teachers Retirement System (NYSTRS)
New York
$884K – – –
Brown Advisory
46
Brown Advisory
Maryland
$875K – – –
1CM
47
1492 Capital Management
Wisconsin
$731K – – –
CS
48
Credit Suisse
Switzerland
$701K +$128K +3,411 +24%
California State Teachers Retirement System (CalSTRS)
49
California State Teachers Retirement System (CalSTRS)
California
$661K +$12.9K +343 +2%
MAM
50
Martingale Asset Management
Massachusetts
$653K +$11.1K +295 +2%
1
2
3 4 5

ANIP Hedge Fund Activity: Q4 2022 in Review

126 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q4 2022, worth a combined $391M — up 18% from $330M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new ANIP positions and 18 closed out — a net gain of 1 holder — while 46 added to existing stakes and 33 trimmed.

The largest buyer was Rubric Capital Management (New York), adding an estimated $3.35M. The largest seller was Balyasny Asset Management, exiting entirely with an estimated $4.47M sold.

  • 126 institutional investors held ANI Pharmaceuticals (ANIP) as of Q4 2022, unchanged from Q3 2022.
  • Funds reported $391M of ANI Pharmaceuticals stock for Q4 2022, up 18% quarter-over-quarter.
  • 19 funds opened new ANI Pharmaceuticals positions in Q4 2022 and 18 closed out, a net change of +1 holder.
  • The largest ANI Pharmaceuticals buyer in Q4 2022 was Rubric Capital Management (New York), an estimated $3.35M added.
  • The largest ANI Pharmaceuticals seller in Q4 2022 was Balyasny Asset Management, an estimated $4.47M sold.

Based on aggregated 13F filings for Q4 2022.